Quantum BioPharma files supplement on share consolidation vote
What it means
- What to watch: In healthcare, timing is everything — trial results, FDA updates and pricing shifts are the real movers.
- How the stock is trading: $QNTM -4.52% in the latest session.
- Timing: Filed after the close: the price beside it finished its day before the story existed, so the next session gets the first real vote.
Where the stock stands
$QNTM last changed hands at $2.11, -4.52% on the session, 83% below its 52-week high of $12.42 and 2.4% above its low of $2.06 — within a tenth of its 52-week low. Over the year it has ranged 503% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $QNTM page.
How much coverage it is getting
Nothing else on $QNTM in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare moves on deadlines: trial outcomes, regulatory decisions and pricing rules. One drug can shift a company, while a policy change can ripple across the whole sector. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
Coming up
$QNTM earnings tomorrow. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $QNTM page has charts, filings and a valuation model. Since one outlet dominates, checking another is key. Wook AI can pull live data and run the numbers — how far $QNTM is from its peak, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $QNTM. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.